Olympus and Bracco Diagnostics have entered a strategic co-marketing agreement to promote the role of endoscopic ultrasound (EUS) with contrast in the characterization of focal liver lesions.
The technology, called contrast-enhanced harmonic endoscopic ultrasound (CH-EUS), is primed to open pathways for more innovative and timely diagnosis and treatment of liver disease, the companies said.
CH-EUS is the use of a contrast agent containing microbubbles and an endoscopic ultrasound system designed to allow the detection of microbubbles within the vasculature, with the intent to provide a more detailed view of potential pathology.
Under terms of the agreement, Olympus will co-market Bracco Diagnostic's Lumason ultrasound-enhancing agent.
